10x Genomics Director Sarah Teichmann Receives Restricted Stock Units

This SEC Form 4 filing reports that Sarah A. Teichmann, a director of 10x Genomics, Inc., was granted 8,829 restricted stock units (RSUs) on June 4, 2026. The RSUs represent a contingent right to receive one share of Class A Common Stock each upon vesting. According to the filing, 1/4th of the RSUs will vest on each quarterly anniversary starting from May 21, 2026, provided Teichmann continues as a service provider through each vesting date. Following this transaction, Teichmann's total holdings in 10x Genomics Class A Common Stock increased to 35,609 shares. The filing was signed by Randy Wu as Attorney-in-Fact for Sarah A. Teichmann on June 8, 2026. This transaction represents a standard equity compensation arrangement for corporate directors.